PitchSend

argenx SE Investor Day Presentation Deck

ASyS and DM: Anti-Jo-1 and Anti-Mi-2 Patients Respond to Rituximab DOI-free Survival Probability 10 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 8 argenx 12 16 20 24 28 TIME (weeks) 32 Aggarwal et al, Arthritis Rheumatol. 2015 (Wilcoxon p<0.001) no AutoAb other AutoAb Mi-2 Jo-1 36 40 44 Shorter time to improvement in patients positive for anti-Jo-1 and anti-Mi-2 autoantibodies Anti-Jo-1 and anti-Mi-2 levels decreased after B-cell depletion Correlation of anti-Jo-1 and anti-Mi-2 titers with disease activity measures Endpoint based on 6 measures: PhGA, PTGA, HAQ, MMT-8, muscle enzymes, extramuscular disease activity score Anti-Jo-1 and anti-Mi-2 autoantibodies are predictive biomarkers for response 32

View entire presentation